Lapuleucel-T

N/A

Report date: 2022/11/25 17:42:42

Base Information

Drug NameLapuleucel-T
Drug Alias NameDN24-02Cancer vaccine HER-2/neuHER-2/neu cancer vaccineNeuvengeBA-7072 +[7] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionT lymphocytes stimulantsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsCarcinoma, Transitional Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDendreon Uk Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDendreon Corp
Active IndicationsN/A
Inactive IndicationsCarcinoma, Transitional Cell

Other Information

ATC CodeN/A
Related LinksN/A